<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211363</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ-151-301</org_study_id>
    <nct_id>NCT04211363</nct_id>
  </id_info>
  <brief_title>Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis</brief_title>
  <acronym>DERMIS-1</acronym>
  <official_title>A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcutis Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcutis Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day&#xD;
      for 56 days by subjects with chronic plaque psoriasis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or&#xD;
      vehicle is applied once daily x 8 weeks to subjects with psoriasis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Actual">November 16, 2020</completion_date>
  <primary_completion_date type="Actual">November 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment Scale (IGA) Score Change</measure>
    <time_frame>Week 8</time_frame>
    <description>Achievement of an IGA score of 'clear' or 'almost clear' plus a 2-grade improvement from Baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of Psoriasis Area Severity Index 75 (PASI-75)</measure>
    <time_frame>Week 8</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intertriginous IGA (I-IGA) score of 'clear' or 'almost clear' PLUS a 2-grade improvement</measure>
    <time_frame>Week 8</time_frame>
    <description>For subjects with intertriginous area involvement, and with severity of the intertriginous lesions at least 'mild' (intertriginous IGA (I-IGA) ≥2) at Baseline, achievement of 'I-IGA' score of 'clear' or 'almost clear' PLUS a 2-grade improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Worst Itch Numerical Rating Score (WI-NRS)</measure>
    <time_frame>Week 2, Week 4, Week 8</time_frame>
    <description>In subjects with WI-NRS pruritus score ≥ 4 at baseline, achievement of a 4-point reduction in WI-NRS pruritus score. The WI-NRS is a 10 point scale with 0 as no itch and 10 as the worst itch imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psoriasis Symptoms Diary (PSD) score</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>The PSD evaluates subject psoriasis-related symptoms and experiences over the past 24-hours. Item scores range from 0 to 10, with higher scores indicating a worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieving Psoriasis Area Severity Index-50 (PASI-50)</measure>
    <time_frame>Week 2, Week 4, Week 8</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of Psoriasis Area Severity Index-90 (PASI-90)</measure>
    <time_frame>Week 8</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">439</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>ARQ-151 cream 0.3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARQ-151 cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-151 0.3% cream</intervention_name>
    <description>ARQ-151 0.3% cream</description>
    <arm_group_label>ARQ-151 cream 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-151 vehicle cream</intervention_name>
    <description>ARQ-151 vehicle cream</description>
    <arm_group_label>ARQ-151 cream vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants legally competent to sign and give informed consent and if appropriate&#xD;
             assent as required by local laws&#xD;
&#xD;
          -  Males and females ages 2 years and older (inclusive)&#xD;
&#xD;
          -  Clinical diagnosis of psoriasis vulgaris of at least 6 months duration (3 months for&#xD;
             children) as determined by the Investigator&#xD;
&#xD;
          -  Females of childbearing potential (FOCBP) must have a negative pregnancy test at&#xD;
             Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must&#xD;
             agree to use at least one form of highly effective contraception throughout the trial.&#xD;
&#xD;
          -  In good health as judged by the Investigator, based on medical history, physical&#xD;
             examination, serum chemistry labs, hematology values, and urinalysis.&#xD;
&#xD;
          -  Subjects considered reliable and capable of adhering to the Protocol and visit&#xD;
             schedule, according to the judgment of the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned excessive exposure of treated area(s) to either natural or artificial&#xD;
             sunlight, tanning bed or other LED.&#xD;
&#xD;
          -  Females who are pregnant, wishing to become pregnant during the study, or are&#xD;
             breast-feeding.&#xD;
&#xD;
          -  Previous treatment with ARQ-151 or its active ingredient&#xD;
&#xD;
          -  Subjects with any serious medical condition or laboratory abnormality that would&#xD;
             prevent study participation or place the subject at significant risk, as determined by&#xD;
             the Investigator.&#xD;
&#xD;
          -  Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation&#xD;
             of investigational product&#xD;
&#xD;
          -  Subjects who are unable to communicate, read or understand the local language, or who&#xD;
             display another condition, which in the Investigator's opinion, makes them unsuitable&#xD;
             for clinical study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 127</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 112</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 120</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 123</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 136</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 118</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 131</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 137</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 105</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 114</name>
      <address>
        <city>Plainfield</city>
        <state>Illinois</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 102</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 111</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 125</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 138</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 101</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 116</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 139</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 129</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 121</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 130</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 108</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 115</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 124</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 134</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 128</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 113</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 135</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 104</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 119</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 110</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 117</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 132</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 103</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 122</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 133</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 140</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2C 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 109</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 106</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 107</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 126</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <disposition_first_submitted>September 29, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 4, 2021</disposition_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

